Canton Strategic Holdings (CNTN) Return on Capital Employed (2022 - 2026)
Canton Strategic Holdings (CNTN) reported Return on Capital Employed of 7.84% for Q1 2026, up 583890.0% on a YoY basis from N/an in Q1 2025, and down 130.76% quarter-over-quarter from 3.4% in Q4 2025.
Canton Strategic Holdings (CNTN) Return on Capital Employed (2022 - 2026) Analysis & Trends
Canton Strategic Holdings has reported Return on Capital Employed for 5 years, with the latest figure at 7.84% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 583890.0% year-over-year to 7.84%; the trailing twelve-month figure through Mar 2026 stood at 7.84% (up 583890.0% YoY), and the FY2025 full-year result was 3.43%, up 24861.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 7.84%, down from 3.4% in the prior quarter.
- The five-year high for Return on Capital Employed was 18004.79% in Q2 2025, with the low at 5846.74% in Q1 2025.
- Historically, Return on Capital Employed has averaged 557.55% across 5 years, with a median of 129.79% in 2024.
- The largest YoY upside for Return on Capital Employed was 1813458 bps in 2025 against a maximum downside of 573424 bps in 2025.
- Canton Strategic Holdings' Return on Capital Employed stood at 110.85% in 2022, then tumbled by 63 bps to 180.39% in 2023, then plunged by 232 bps to 598.32% in 2024, then jumped by 99 bps to 3.4% in 2025, then slumped by 131 bps to 7.84% in 2026.
- The last three Return on Capital Employed figures came in at 7.84% (Q1 2026), 3.4% (Q4 2025), and 288.64% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Canton Strategic Holdings | 699.97 Mn | 658.44 Mn | - | -7.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.84% |
| Dec 31, 2025 | -3.40% |
| Sep 30, 2025 | -288.64% |
| Jun 30, 2025 | 18,004.79% |
| Mar 31, 2025 | -5,846.74% |
| Dec 31, 2024 | -598.32% |
| Sep 30, 2024 | -245.93% |
| Jun 30, 2024 | -129.79% |
| Mar 31, 2024 | -112.49% |
| Dec 31, 2023 | -180.39% |
| Sep 30, 2023 | -351.39% |
| Jun 30, 2023 | -286.64% |
| Mar 31, 2023 | -197.06% |
| Dec 31, 2022 | -110.85% |
| Sep 30, 2022 | -63.39% |
| Jun 30, 2022 | -36.45% |
| Mar 31, 2022 | -67.15% |